EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study

Lan Lan, Yuxin Lin, Binfeng Yu, Yin Wang, Hong Pan, Huijing Wang, Xiaowei Lou, Xiabing Lang, Qiankun Zhang, Lie Jin, Yi Yang, Liang Xiao und 2 weitere

American Journal of Nephrology · 2024

DOI: 10.1159/000535010 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Lan Lan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Glomerulosclerosis, Focal Segmental, Nephrotic Syndrome, Nephrosis, Lipoid. Die Arbeit wurde bisher 21-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rituximab has been proven effective and safe in pediatric patients with frequently relapsing or steroid-dependent nephrotic syndrome (FR/SDNS). We aimed to analyze the efficacy and safety of rituximab in adult FR/SDNS patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).

Methods

A retrospective cohort study at three nephrology centers in China included adult FR/SDNS patients with biopsy-proven MCD or FSGS. Primary outcomes were relapse frequency and first relapse-free survival time. Adverse events were well recorded, and logistic regression analyses were used to investigate the risk factors of relapse.

Results

Eighty-one patients (age, 25.0 years; interquartile range, 20.0–40.5; 67% males; 82.7% MCD) received an average rituximab dose of 1,393.8 ± 618.7 mg/2 years during the 2-year follow-up period. The relapse frequency, calculated as the ratio of relapse times to follow-up years, significantly decreased after rituximab treatment (0.04 [0.00, 0.08] vs. 1.71 [1.00, 2.45], p < 0.001). The first relapse-free survival time was 16.7 ± 8.0 months. Fifty-seven patients (70.4%) achieved cessation of corticosteroids and immunosuppressants within 3 months after the first rituximab infusion. Adverse events were mostly mild, and no severe treatment-related adverse events were observed. Low serum albumin level before rituximab and high CD56+CD16+ natural killer cell count after rituximab were independent risk factors of relapse within 2 years after rituximab treatment.

Conclusion

Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulosclerosis, Focal SegmentalNephrotic SyndromeNephrosis, LipoidMaleAdultHumansChildFemaleRituximabRetrospective StudiesImmunosuppressive AgentsRecurrenceChronic DiseaseTreatment Outcome

Stichwörter der Autor:innen

AdultFocal segmental glomerulosclerosisMinimal change diseaseNephrotic syndromeRituximab

Substanzen

RituximabImmunosuppressive Agents

Autor:innen und Institutionen

  • Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Institute of Nephrology, Zhejiang University, Hangzhou, China.
  • Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China.
  • National Key Clinical Department of Kidney Diseases, Hangzhou, China.
  • Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China.
  • Division of Nephrology, Lishui Central Hospital, Lishui, China.

Zitieren

APA

Lan, L., Lin, Y., Yu, B., Wang, Y., Pan, H., Wang, H., Lou, X., Lang, X., Zhang, Q., Jin, L., Yang, Y., Xiao, L., Chen, J., & Han, F. (2024). Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study. American Journal of Nephrology. https://doi.org/10.1159/000535010

Vancouver

Lan L, Lin Y, Yu B, Wang Y, Pan H, Wang H, et al. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study. American Journal of Nephrology. 2024. doi:10.1159/000535010

BibTeX
@article{Lan2024,
  author = {Lan, Lan and Lin, Yuxin and Yu, Binfeng and Wang, Yin and Pan, Hong and Wang, Huijing and Lou, Xiaowei and Lang, Xiabing and Zhang, Qiankun and Jin, Lie and Yang, Yi and Xiao, Liang and Chen, Jianghua and Han, Fei},
  title = {Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study},
  journal = {American Journal of Nephrology},
  year = {2024},
  doi = {10.1159/000535010}
}
Kostenlos starten →